GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myeloma at ASCO. Adding Blenrep ...
Whether it's a streaming service or a meditation app, subscription services can add up quickly, especially when you forget about canceling a free trial. Nearly a quarter of Americans spend over $100 a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback